Privileged Scaffold for Drug Design and Activity Improvement - Part III

2021 ◽  
Vol 21 (28) ◽  
pp. 2513-2513
Author(s):  
Yongtao Duan ◽  
Hai-liang Zhu
Author(s):  
Faheem ◽  
Banoth Karan Kumar ◽  
Kondapalli Venkata Gowri Chandra Sekhar ◽  
Subhash Chander ◽  
Selvaraj Kunjiappan ◽  
...  

RSC Advances ◽  
2018 ◽  
Vol 8 (37) ◽  
pp. 20894-20921 ◽  
Author(s):  
Mariateresa Badolato ◽  
Francesca Aiello ◽  
Nouri Neamati

2,3-Dihydroquinazolin-4-one (DHQ) belongs to the class of nitrogen-containing heterocyclic compounds representing a core structural component in various biologically active compounds.


2020 ◽  
Vol 20 (28) ◽  
pp. 2535-2577
Author(s):  
Zhen Zhang ◽  
Bing Shu ◽  
Yaodong Zhang ◽  
Girdhar Singh Deora ◽  
Qing-Shan Li

: Thiazole is an important 5-membered heterocyclic compound containing nitrogen and sulfur atoms with various pharmaceutical applications including anti-inflammatory, anti-cancer, anti-viral, hypoglycemic, anti-bacterial and anti-fungal activities. Until now, the FDA-approved drugs containing thiazole moiety have achieved great success such as dasatinib and dabrafenib. In recent years, considerable research has been focused on thiazole derivatives, especially 2,4,5-trisubstituted thiazole derivatives, due to their multiple medicinal applications. This review covers related literature in the past 20 years, which reported the 2,4,5-trisubstituted thiazole as a privileged scaffold in drug design and activity improvement. Moreover, this review aimed to provide greater insights into the rational design of more potent pharmaceutical molecules based on 2,4,5-trisubstituted thiazole in the future.


Sign in / Sign up

Export Citation Format

Share Document